NEW YORK, July 11, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the launch of its newly redesigned corporate website, www.luciddx.com. "We designed the new website to highlight our mission to prevent esophageal cancer and offer patients, healthcare professionals, investors, and other interested parties a user-friendly experi ...

NEW YORK, June 12, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that the 4,000th firefighter has undergone esophageal precancer testing using Lucid's EsoGuard® Esophageal DNA test as part of a #CheckYourFoodTube Precancer Testing Event. In partnership with physicians from Mass General Brigham, Boston's Local 718 Internationa ...

Exhibit 99.1 Lucid Diagnostics Provides Business Update and First Quarter 2024 Financial Results Quarterly EsoGuardtest volume increased 10 percent Strengthened balance sheet following completion of $29.8 million Series B Preferred Stock Of ering MolDX pre-submission meeting scheduled for July 17, 2024 Conference call and webcast to be held today, May 13 at 8:30 AM EDT NEW YORK, May 13, 2024 - Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diag ...

Financial Data and Key Metrics Changes - The company reported a non-GAAP loss of $9.4 million for Q1 2024, reflecting a $500,000 sequential improvement compared to Q4 2023 and a $400,000 improvement year-over-year [15][37] - Revenue for Q1 2024 was just over $1 million, flat compared to Q4 2023 but representing a 124% increase year-over-year [38][95] - The average quarterly burn rate for the trailing four quarters was $9.5 million, with Q1 2024 burn including $7 million from ongoing operations and $2.5 million from a management services agreement [37][67] Business Line Data and Key Metrics Changes - Test volume for Q1 2024 was 2,420 tests, a 10% increase quarter-over-quarter and a 31% increase year-over-year [38][95] - The gross margin at current volumes is approximately 90%, facilitating the business's ability to generate revenue [97] - The company has implemented a streamlined telehealth operation to enhance testing efficiency, particularly during high-volume health events [7][95] Market Data and Key Metrics Changes - The total addressable market opportunity for the company's tests is approximately $50 billion, with over 30 million patients at risk for esophageal cancer [6] - The average allowed amount for out-of-network claims remains stable at just under the Medicare rate of $1,938 per test [76][99] - Approximately 75% of claims submitted have been adjudicated, with nearly half resulting in an allowable amount by insurance companies [128] Company Strategy and Development Direction - The company is focused on securing medical policy coverage with regional plans and engaging in direct contracting with self-insured entities [60][80] - The company plans to ramp up its direct contracting initiatives during the second half of the year, targeting large groups of patients [79] - The company is actively pursuing biomarker legislation states to enhance coverage opportunities [9][80] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism regarding the upcoming MolDX pre-submission meeting scheduled for July 17, which aims to secure coverage for EsoGuard [60][116] - The management highlighted the importance of improving revenue cycle management processes, including prior authorization programs to reduce denials [67][76] - The company is confident in its technology's ability to detect pre-cancer effectively, which is critical for impacting cancer death rates [64][77] Other Important Information - The company completed a $29.8 million Series B preferred stock offering, strengthening its balance sheet and extending its operational runway [75][76] - The company has not experienced any device failures with EsoCheck in over 10,000 tests, contrasting with issues faced by competitors [68][84] - The company is preparing for a significant presence at the upcoming DDW meeting, which is a major event in the gastroenterology field [47][98] Q&A Session Summary Question: What are the expectations for the upcoming MolDX pre-submission meeting? - The meeting aims to review data with the MolDX group for a technical assessment seeking coverage of EsoGuard under Medicare [108] Question: Can you provide an update on the reimbursement landscape? - Approximately 75% of claims submitted have been adjudicated, with nearly half resulting in allowable amounts, indicating progress in the reimbursement process [128] Question: How does the company view the competitive landscape, especially with recent recalls in the industry? - The company believes that recent issues faced by competitors, such as the Cytosponge recall, may provide a competitive advantage for its products [119][120]

For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-40901 Securities registered pursuant to Section 12(b) of the Exchange Act: | Title of each Class | Trading Symbol(s) ...

EsophaCap device recalled due to recent publication of serious device failures Lucid Diagnostics' EsoCheck® unaffected by recall and remains the gold standard for non-endoscopic cell collection NEW YORK, May 9, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), announced that the legacy EsophaCap sponge-on-a-string (SOS) esophage ...

Final closing yields total gross proceeds of $29.8 million from offering Mr. Matheis serves as President and CEO of Sentara Health, one of the largest not-for-profit integrated health systems in the U.S., which encompasses hospitals, a physician group, and an affiliated health plan NEW YORK, May 7, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAV ...

Conference Call and Webcast at 8:30AM Eastern Time NEW YORK, May 2, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ), today announced that it will host a business update conference call and webcast on Monday, May 13, 2024, at 8:30 AM ET. During the call, Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will provide a busine ...

NEW YORK, April 29, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM), is partnering with the Esophageal Cancer Action Network (ECAN) to highlight Esophageal Cancer Awareness Month. ECAN, a leading patient advocacy organization focused on increasing esophageal cancer education, advocacy, awareness, and research, was founded 15 years ago by Mindy M ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number: 001-40901 LUCID DIAGNOSTICS INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 82-5488042 (State or Other Ju ...